SkinBioTherapeutics awarded Australian patent for SkinBiotix

Life sciences company SkinBioTherapeutics announced the granting of the first patent for its ‘SkinBiotix’ technology in Australia on Friday.

The AIM-traded firm said the patent granted covered the use of “specific probiotic bacteria” and lysates in the treatment of skin in health and disease.

It marked the company's first patent to progress to grant from within its portfolio of patents pending estate.

The patent, numbered 2013246701 and entitled 'probiotic bacteria', would until 15 March 2033.

SkinBioTherapeutics said the patent was in active prosecution in other locations worldwide, including Europe, the US and China.

“The Australian skincare market is a key global market,” said CEO Dr Catherine O'Neill.

“The progression and successful grant of the first national patent to emerge from the company's Skinbiotix patent family underpins the commercial potential worldwide.

“This is a step forward in preparing for human trials, which are scheduled for 2018.”